)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Atossa Therapeutics
Atossa Therapeutics (ATOS) investor relations material
Atossa Therapeutics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary10 Nov, 2026
Executive summary
Clinical-stage pipeline centers on oral (Z)-endoxifen across breast cancer and rare-disease indications; no marketed products or current revenue.
Q3 expenses and net loss declined YoY, but 9M operating cash use rose to $24.7M and cash fell to $20.6M; additional funding is needed to continue planned operations.
Financial highlights
Q3 2026 operating expenses and operating loss were each $5.9M, versus $9.3M YoY; net loss was $5.6M versus $8.7M.
Q3 basic and diluted loss per share was $0.56 versus $1.01; 9M loss per share was $2.58 versus $2.76.
9M operating expenses were $24.5M versus $25.7M; net loss was $23.7M versus $23.8M.
9M R&D expense fell 13% to $13.1M, primarily from lower trial and regulatory consulting costs; G&A rose 7% to $11.4M, reflecting litigation and other legal costs, partly offset by lower compensation.
9M interest income was $0.7M versus $1.9M, primarily reflecting lower average invested cash balances; no income tax provision was recorded.
Outlook and guidance
Existing resources are expected to be insufficient for planned operations over the next 12 months; additional capital is needed, with no assurance financing will be available on acceptable terms.
EVANGELINE top-line data are expected in Q2 2027 after participants complete the 28-week treatment protocol; enrollment was completed in Q2 2026.
FDA IND clearance for (Z)-endoxifen in DMD and McCune-Albright syndrome is anticipated by early 2027, with Phase 2 trial starts expected in 2027.
Final 24-month Karisma durability data were received in Q3 2026; Karisma follow-up results and selected I-SPY 2 data are scheduled for presentation at SABCS in December 2026.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Atossa Therapeutics
- (Z)-Endoxifen advances as a potent, dual-action therapy for breast cancer and rare diseases.ATOS
Corporate presentation - Net loss increased to $18.1M, cash reserves fell, and $4.5M in new capital was raised.ATOSQ2 2026
- Adaptive trials and endoxifen are advancing breast cancer care with faster, patient-focused innovation.ATOSStatus update
- Net loss widened to $9.6M as R&D and legal costs rose, with key FDA designations achieved.ATOSQ1 2026
- Proxy seeks approval for director elections, auditor, reverse split, and executive pay; board is majority independent.ATOSProxy filing
- (Z)-endoxifen shows best-in-class potential in breast cancer and rare diseases, with strong financials.ATOSCorporate presentation
- Operating loss widened as R&D spending surged for (Z)-endoxifen clinical advancement.ATOSQ4 2025
- Annual Meeting to vote on directors, auditor, reverse split, compensation, and governance.ATOSProxy filing
- Multiple phase II trials and AI-driven research position endoxifen for broad breast cancer impact.ATOSSmall-Cap Growth Virtual Investor Conference
Next Atossa Therapeutics earnings date
Q4 202625 Mar, 2027
Atossa Therapeutics
Next Atossa Therapeutics earnings date
Q4 202625 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Atossa Therapeutics Inc. is a clinical-stage biopharmaceutical company developing medicines that address significant unmet medical needs in oncology, with a specific focus on breast cancer. The company's lead program is Endoxifen, an active metabolite of tamoxifen, currently in clinical trials for the treatment and prevention of breast cancer. Additionally, Atossa is working on AT-H201 for lung injury caused by cancer treatment and is involved in developing immunotherapy/chimeric antigen receptor therapy programs. The company is headquartered in Seattle, Washington, and its shares are listed on the NASDAQ.